Alan Dalkin is an Endocrinology/Metabolic physician affiliated with University of Virginia. OpenAlex indexes 77 publications with 3,663 citations (h-index 33).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingMedicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Hormonal (systemic)
47.3%l-Thyroxine41.1%Levothyroxine Sodium77%Synthroid23%Part D≥123 patientsl-Triiodothyronine3.9%Liothyronine Sodium100%Part D≥16 patients+ 2 more classes in this area
Metabolism & gastrointestinal
28.2%Insulin Analog12.3%Lantus Solostar23%Novolog Flexpen20%Humalog13%Lantus13%Novolog12%Humalog Kwikpen U-10011%Basaglar Kwikpen U-1009%Part D<11 patientsBiguanide (metformin)7.8%Metformin Hcl Er56%Metformin Hcl44%Part D≥19 patients+ 6 more classes in this area
Cardiovascular
17.9%Statin6.9%Atorvastatin Calcium68%Rosuvastatin Calcium33%Part D<11 patientsACE inhibitor3%Lisinopril100%Part D≥15 patients+ 5 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 1998–2000 per NIH RePORTER. The latest:
- PROSTATE CANCER--THE ROLE OF ACTIVIN AND FOLLISTATIN
University of Virginia Charlottesville
FY2000$219,228R01AG016663 - PROSTATE CANCER--THE ROLE OF ACTIVIN AND FOLLISTATIN
University of Virginia Charlottesville
FY1999R01AG016663 - PROSTATE CANCER--THE ROLE OF ACTIVIN AND FOLLISTATIN
University of Virginia Charlottesville
FY1998R01AG016663
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Charles Landen, MD
University of Virginia
Stephen Caldwell
University of Virginia
James Platts-Mills, MD
University of Virginia
Eric Houpt
University of Virginia
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”